Ken Okumura

Ken Okumura

Auto-generated profile, based on publicly available information

Ken Okumura

Division of Cardiology Saiseikai Kumamoto Hospital Kumamoto Japan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2019 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
HOHideharu Okamatsu
Hideharu Okamatsu
JKJunjiro Koyama
Junjiro Koyama
YSYoshirou Sakai
Yoshirou Sakai
KNKoudai Negishi
Koudai Negishi
KHKatsuhide Hayashi
Katsuhide Hayashi
KOKen Okumura
Ken Okumura

1 April 2020 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
KOKen Okumura
Ken Okumura
HTHirofumi Tomita
Hirofumi Tomita
MNMichikazu Nakai
Michikazu Nakai
EKEitaro Kodani
Eitaro Kodani
MAMasaharu Akao
Masaharu Akao
FGfor the J-RISK AF Research Group
for the J-RISK AF Research Group
The CHA2DS2-VASc score (congestive heart failure, hypertension, age 75 years or older, diabetes, prior stroke/transient ischemic attack–vascular disease, age 65-74 years, sex category) is widely used in Europe and the United States for thromboembolic risk stratification in patients with nonvalvular atrial fibrillation (NVAF),1,2 whereas CHADS2 (congestive heart failure, hypertension, aged 75 years or older, diabetes, prior stroke/transient ischemic attack) score is used in Japan.3 In a previous study,4 we showed that both scores are useful for risk stratification in Japanese NVAF patients. But all CHADS2 score factors may not necessarily represent risks for thromboembolism. Our previous pooled data of the J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) Registry, Fushimi AF Registry, and Shinken Database showed that, for patients without oral anticoagulants (OAC), age 75 years or older, hypertension, and previous stroke or transient ischemic attack were independent risk factors associated with ischemic stroke, but diabetes or heart failure were not.5 The pooled data also showed that the annual ischemic stroke rate was 0.9%, 1.5%, and 2.7% in individuals with a CHADS2 score of 1, 2, and 3, respectively, which was lower than those shown in the original data.5,6 These findings suggest some differences in risk factors associated with thromboembolism by race and region.

7 September 2015 in EP Europace
Verified
Journal Article
Open access
TITaihei Itoh
Taihei Itoh
MKMasaomi Kimura
Masaomi Kimura
HTHirofumi Tomita
Hirofumi Tomita
SSShingo Sasaki
Shingo Sasaki
SOShingen Owada
Shingen Owada
KOKen Okumura
Ken Okumura
Although contact force (CF)-guided circumferential pulmonary vein isolation (CPVI) for paroxysmal atrial fibrillation (PAF) is useful, AF recurrence at long-term follow-up still remains to be resolved. The purpose of this study was to assess safety and efficacy of CF-guided CPVI and to compare residual conduction gaps during CPVI and long-term outcome between the conventional (non-CF-guided) and the CF-guided CPVI. We studied the 50 consecutive PAF patients undergoing CPVI by a ThermoCool EZ Steer catheter (conventional group, mean age 61 ± 10 years) and the other 50 consecutive PAF patients by a ThermoCool SmartTouch catheter (CF group, 65 ± 11 years). The procedure parameters and residual conduction gaps during CPVI, and long-term outcome for 12 months were compared between the two groups. Circumferential pulmonary vein isolation was successfully accomplished without any major complications in both groups. Total procedure and total fluoroscopy times were both significantly shorter in the CF group than in the conventional group (160 ± 30 vs. 245 ± 61 min, P < 0.001, and 17 ± 8 vs. 54 ± 27 min, P < 0.001, respectively). Total number of residual conduction gaps was significantly less in the CF group than in the conventional group (2.7 ± 1.7 vs. 6.3 ± 2.7, P < 0.05). The AF recurrence-free rates after CPVI during 12-month follow-up were 96% (48/50) in the CF group and 82% (41/50) in the conventional group (P = 0.02 by log rank test). Multivariate Cox regression analysis further supported this finding. Contact force-guided CPVI is safe and more effective in reducing not only the procedure time but also the AF recurrence than the conventional CPVI, possibly due to reduced residual conduction gaps during CPVI procedure.

1 December 2017 in American Heart Journal
Verified
Journal Article
Open access
KOKen Okumura
Ken Okumura
GLGregory Y.H. Lip
Gregory Y.H. Lip
MAMasaharu Akao
Masaharu Akao
KTKimihiko Tanizawa
Kimihiko Tanizawa
MFMasayuki Fukuzawa
Masayuki Fukuzawa
TYTakeshi Yamashita
Takeshi Yamashita
Edoxaban-a non-vitamin K antagonist oral anticoagulant (NOAC)- 60-mg and 30-mg once-daily dose regimens are noninferior versus well-managed warfarin for the prevention of stroke or systemic embolic events (SEE) with less major bleeding in patients with nonvalvular atrial fibrillation (NVAF). There are no published data from phase 3 clinical trials specifically evaluating the use of NOACs in elderly NVAF patients, especially those considered ineligible for available oral anticoagulants. The Edoxaban Low-Dose for EldeR CARE AF patients (ELDERCARE-AF) study is a phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study that will compare the safety and efficacy of once-daily edoxaban 15 mg versus placebo in Japanese patients with NVAF ≥80 years of age who are considered ineligible for standard oral anticoagulant therapy. A total of 800 patients (400 in each treatment group) are planned for randomization (1:1) to either edoxaban or placebo using a stratified randomization method with CHADS2 index score (2 points, ≥3 points) as a factor. The primary efficacy end point is the time to first onset of stroke or SEE. The net clinical outcome is the composite of stroke, SEE, major bleeding, and all-cause mortality. The primary safety end point is the incidence of major bleeding. The treatment period will continue until 65 patients with the primary efficacy events (ie, stroke or SEE) have been observed (2- to 2.5-year expected mean treatment period). The results of ELDERCARE-AF may provide clarity as to the efficacy and safety of edoxaban for the prevention of stroke or SEE in this high-risk population.

1 April 2016 in Annals of General Psychiatry
Verified
Journal Article
Open access
PDF file
NMNorifumi Metoki
Norifumi Metoki
NSNorio Sugawara
Norio Sugawara
JHJoji Hagii
Joji Hagii
SSShin Saito
Shin Saito
HSHiroshi Shiroto
Hiroshi Shiroto
NYNorio Yasui-Furukori
Norio Yasui-Furukori
Approximately one-third of stroke survivors suffer from post-stroke depression (PSD) in the acute or chronic stages. The presence of PSD in the acute stage after stroke is reportedly associated with poor patient prognosis; therefore, early recognition and treatment of PSD may alleviate these consequences. The aim of the current study was to examine the relationship between the lesion location and the presence of early depressive symptoms after acute ischemic stroke in Japanese patients. Our study included 421 patients who suffered from acute ischemic stroke. On the day of admission, the lesion location was determined using magnetic resonance imaging (MRI). Stroke severity was measured on the seventh day of hospitalization withat the National Institutes of Health Stroke Scale (NIHSS). On the tenth day of hospitalization, depressive symptoms were measured and functional assessments were performed with the Japan Stroke Scale (Depression Scale) (JSS-D) and functional independence measure (FIM), respectively. A total of 71 subjects (16.9 %) were diagnosed with depression. According to the multiple logistic regression analysis, the infarcts located at frontal and temporal lobes were found to be a significant independent risk factor of early depressive symptoms in the acute stage of stroke. Patients suffering from acute ischemic stroke, particularly in the frontal and temporal lobes, should be carefully assessed to detect and treat early depressive symptoms; such treatment may improve patient outcomes.

1 June 2015 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
HTHirofumi Tomita
Hirofumi Tomita
JHJoji Hagii
Joji Hagii
NMNorifumi Metoki
Norifumi Metoki
SSShin Saito
Shin Saito
HSHiroshi Shiroto
Hiroshi Shiroto
KOKen Okumura
Ken Okumura